Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 6Active not recruiting 6Terminated 2Withdrawn 1Not yet recruiting 1Completed 1Available 1Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 77Breast Neoplasms 53Colorectal Neoplasms 52Neoplasms 40Advanced Solid Tumors 34Prostatic Neoplasms 31Multiple Myeloma 31Ovarian Neoplasms 28Neoplasm Metastasis 28Recurrence 27Lung Neoplasms 27Carcinoma, Hepatocellular 27Pancreatic Neoplasms 26Advanced Solid Tumor 22Small Cell Lung Carcinoma 20Leukemia, Myeloid, Acute 20Melanoma 18Endometrial Neoplasms 18Triple Negative Breast Neoplasms 17Squamous Cell Carcinoma of Head and Neck 14Lymphoma, Follicular 14Stomach Neoplasms 13Lymphoma, B-Cell 13Glioma 13Glioblastoma 13Uterine Cervical Neoplasms 12Lymphoma 11Head and Neck Neoplasms 11Solid Tumor 10Myasthenia Gravis 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Neurofibroma, Plexiform × Clear all
NCT07024394 2025-06-17

Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 1/2 Not yet recruiting
65 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡